Genentech AVAiL Trial Results May Lower Avastin Dosing In NSCLC

Findings that a lower dose of Genentech's Avastin showed a similar treatment effect on progression-free survival as a higher dose in the AVAiL trial in first-line non-small cell lung cancer could impact physician prescribing patterns for the oncologic in lung cancer